CAI
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 7.85 · operating margin 5.6%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. Weekly bias is flat
VENTE TOTALE: 400 000 titres (~12 132 080,00 $ US)
- Insiders
- Brille Brian J
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$12,132,080
Avg sell (VWAP, 90d window) $28.57 vs last close $31.98 (+12.0%)
- Last activity
- 2026-09-17
- Liquidity
- Liquid $171,228,616/day · 20d vol
- Last synced
-
2026-09-25 21:10:13
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-22 | Denton John Russel | Sell | 7,500 | $31.82 | $238,626 | Form 4 |
| 2026-09-17 | Brille Brian J | Sell | 400,000 | $30.33 | $12,132,080 | Form 4 |
| 2026-09-04 | Spetzler David Baxley | Sell | 119,212 | $24.76 | $2,951,117 | Form 4 |
| 2026-09-03 | Spetzler David Baxley | Sell | 84,900 | $25.32 | $2,149,676 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-23
CAI presents a deeply concerning profile: despite adequate short-term liquidity (score 75), the fundamental trend score (35) reveals persistent net losses, negative profitability ratios, and cash-flow inefficiency that…
The first sentence of the analysis written for CAI on 2026-09-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 66.4% | 43.4% | 29.2% | 31.0% | 62.6% | |
| Ebit Margin | -1.4% | -56.2% | -101.2% | -113.8% | 48.9% | |
| Ebitda Margin | 1.4% | -44.4% | -85.2% | -95.1% | 86.5% | |
| Operating Profit Margin | 5.6% | -62.4% | -104.4% | -122.2% | 47.3% | |
| Pretax Profit Margin | -8.4% | -68.4% | -111.5% | -124.1% | 10.0% | |
| Continuous Operations Profit Margin | -66.2% | -68.4% | -111.5% | -124.1% | 9.4% | |
| Net Profit Margin | -66.2% | -68.4% | -111.5% | -124.1% | 9.4% | |
| Bottom Line Profit Margin | -66.2% | -167.0% | -151.1% | -154.7% | 9.4% | |
| Current Ratio | 7.848 | 1.304 | 2.550 | 3.769 | 0.670 | |
| Quick Ratio | 7.848 | 1.065 | 2.035 | 3.426 | 0.670 | |
| Solvency Ratio | -0.940 | -0.082 | -0.114 | -0.113 | 0.072 | |
| Cash Ratio | 6.275 | 0.387 | 0.593 | 0.783 | 0.167 | |
| Price To Earnings Ratio | -14.126 | -10.370 | -15.385 | -17.834 | 18.065 | |
| Price To Earnings Growth Ratio | 0.483 | -0.214 | -0.966 | 0.000 | -1.828 | |
| Forward Price To Earnings Growth Ratio | 0.483 | -0.214 | -0.966 | 0.000 | -1.828 | |
| Price To Earnings Diluted Ratio | -14.505 | -10.370 | -15.385 | -17.834 | 18.065 | |
| Price To Earnings Diluted Growth Ratio | 0.466 | -0.214 | -0.966 | 0.000 | -1.828 | |
| Price To Book Ratio | 13.195 | -2.854 | -3.324 | -4.191 | 0.716 | |
| Price To Sales Ratio | 9.381 | 17.296 | 23.293 | 27.600 | 1.709 | |
| Price To Free Cash Flow Ratio | 113.869 | -28.113 | -23.894 | -21.753 | 8.730 | |
| Price To Operating Cash Flow Ratio | 91.603 | -29.081 | -25.826 | -24.970 | 1.814 | |
| Debt To Assets Ratio | 0.337 | 1.234 | 0.526 | 0.378 | 0.668 | |
| Debt To Equity Ratio | 0.656 | -0.170 | -0.101 | -0.159 | 2.486 | |
| Debt To Capital Ratio | 0.396 | -0.205 | -0.113 | -0.189 | 0.713 | |
| Long Term Debt To Capital Ratio | 0.396 | -0.146 | -0.084 | -0.111 | 0.690 | |
| Financial Leverage Ratio | 1.950 | -0.138 | -0.192 | -0.421 | 3.720 | |
| Working Capital Turnover Ratio | 1.763 | 4.169 | 1.163 | 0.000 | 5.540 | |
| Operating Cash Flow Ratio | 0.654 | -1.482 | -2.902 | -2.087 | 0.865 | |
| Operating Cash Flow Sales Ratio | 0.102 | -0.595 | -0.902 | -1.105 | 0.942 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.804 | 1.034 | 1.081 | 1.148 | 0.208 | |
| Debt Service Coverage Ratio | -8.041 | -1.663 | -8.207 | -3.094 | 1.031 | |
| Interest Coverage Ratio | 0.794 | -5.140 | -10.109 | -11.835 | 2.259 | |
| Short Term Operating Cash Flow Coverage Ratio | 492.041 | -4.087 | -1,653.293 | -5.412 | 1.510 | |
| Operating Cash Flow Coverage Ratio | 0.219 | -0.578 | -1.271 | -1.055 | 0.159 | |
| Capital Expenditure Coverage Ratio | 5.114 | -29.038 | -12.371 | -6.761 | 1.262 | |
| Dividend Paid And Capex Coverage Ratio | 5.114 | -29.038 | -12.371 | -6.761 | 1.168 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.638 | |
| Enterprise Value Multiple | 632.555 | -40.944 | -27.957 | -29.679 | 8.625 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 66.4% | ▲23.0% | ▲19.9% |
| Ebit Margin | -1.4% | ▲54.9% | ▲43.4% |
| Ebitda Margin | 1.4% | ▲45.8% | ▲28.7% |
| Operating Profit Margin | 5.6% | ▲67.9% | ▲52.8% |
| Pretax Profit Margin | -8.4% | ▲60.0% | ▲52.1% |
| Continuous Operations Profit Margin | -66.2% | ▲2.1% | ▲5.9% |
| Net Profit Margin | -66.2% | ▲2.1% | ▲5.9% |
| Bottom Line Profit Margin | -66.2% | ▲100.7% | ▲39.7% |
| Current Ratio | 7.848 | ▲6.544 | ▲4.619 |
| Quick Ratio | 7.848 | ▲6.783 | ▲4.839 |
| Solvency Ratio | -0.940 | ▼-0.858 | ▼-0.705 |
| Cash Ratio | 6.275 | ▲5.888 | ▲4.634 |
| Price To Earnings Ratio | -14.126 | ▼-3.755 | ▼-6.196 |
| Price To Earnings Growth Ratio | 0.483 | ▲0.697 | ▲0.988 |
| Forward Price To Earnings Growth Ratio | 0.483 | ▲0.697 | ▲0.988 |
| Price To Earnings Diluted Ratio | -14.505 | ▼-4.135 | ▼-6.499 |
| Price To Earnings Diluted Growth Ratio | 0.466 | ▲0.681 | ▲0.975 |
| Price To Book Ratio | 13.194 | ▲16.048 | ▲12.486 |
| Price To Sales Ratio | 9.380 | ▼-7.916 | ▼-6.475 |
| Price To Free Cash Flow Ratio | 113.869 | ▲141.982 | ▲104.101 |
| Price To Operating Cash Flow Ratio | 91.603 | ▲120.684 | ▲88.895 |
| Debt To Assets Ratio | 0.337 | ▼-0.898 | ▼-0.292 |
| Debt To Equity Ratio | 0.656 | ▲0.826 | ▲0.114 |
| Debt To Capital Ratio | 0.396 | ▲0.601 | ▲0.276 |
| Long Term Debt To Capital Ratio | 0.396 | ▲0.543 | ▲0.247 |
| Financial Leverage Ratio | 1.950 | ▲2.087 | ▲0.966 |
| Working Capital Turnover Ratio | 1.763 | ▼-2.405 | ▼-0.764 |
| Operating Cash Flow Ratio | 0.654 | ▲2.136 | ▲1.645 |
| Operating Cash Flow Sales Ratio | 0.102 | ▲0.697 | ▲0.414 |
| Free Cash Flow Operating Cash Flow Ratio | 0.804 | ▼-0.230 | ▼-0.051 |
| Debt Service Coverage Ratio | -8.041 | ▼-6.378 | ▼-4.046 |
| Interest Coverage Ratio | 0.793 | ▲5.933 | ▲5.600 |
| Short Term Operating Cash Flow Coverage Ratio | 492.041 | ▲496.128 | ▲725.890 |
| Operating Cash Flow Coverage Ratio | 0.219 | ▲0.797 | ▲0.725 |
| Capital Expenditure Coverage Ratio | 5.114 | ▲34.152 | ▲13.473 |
| Dividend Paid And Capex Coverage Ratio | 5.114 | ▲34.152 | ▲13.492 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▼-0.128 |
| Enterprise Value Multiple | 632.555 | ▲673.499 | ▲524.035 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|---|
| Market cap | $7.62B | $7.13B | $7.13B | $7.13B | $502.6M | |
| Enterprise value | $7.20B | $7.49B | $7.29B | $7.30B | $2.19B | |
| EV / Sales | 8.87x | 18.17x | 23.82x | 28.23x | 7.46x | |
| EV / Op. cash flow | 86.57x | -30.55x | -26.41x | -25.54x | 7.92x | |
| EV / Free cash flow | 107.61x | -29.53x | -24.43x | -22.25x | 38.13x | |
| EV / EBITDA | 632.55x | -40.94x | -27.96x | -29.68x | 8.62x | |
| Net debt / EBITDA | -36.80x | -1.97x | -0.62x | -0.67x | 6.65x | |
| Current ratio | 7.85x | 1.30x | 2.55x | 3.77x | 0.67x | |
| Income quality | -1.22x | 0.87x | 0.81x | 0.89x | 9.99x | |
| Graham number | — | — | — | — | $37 | |
| Graham net-net | $1 | -$11 | -$9 | -$8 | -$93 | |
| Tax burden | 790.1% | 100.0% | 100.0% | 100.0% | 93.9% | |
| Interest burden | 606.0% | 121.6% | 110.2% | 109.1% | 20.5% | |
| Working capital | $870.7M | $50.3M | $147.5M | $379.1M | -$105.6M | |
| Invested capital | $953.2M | $172.4M | $314.3M | $536.5M | $1.68B | |
| Return on assets | -47.8% | -82.0% | -82.7% | -44.7% | 1.1% | |
| Operating ROA | 6.1% | -68.0% | -56.5% | 0.0% | 5.0% | |
| Return on tangible assets | -48.6% | -86.9% | -86.8% | -46.0% | 1.1% | |
| Return on equity | -93.2% | 11.3% | 15.9% | 18.8% | 3.9% | |
| Return on invested capital | 4.5% | -105.2% | -98.5% | -49.5% | 5.3% | |
| Return on capital employed | 4.5% | -144.2% | -100.6% | -54.4% | 6.1% | |
| Earnings yield | -7.1% | -4.0% | -4.8% | -4.5% | 5.5% | |
| Free cash flow yield | 0.9% | -3.6% | -4.2% | -4.6% | 11.5% | |
| Capex / Op. cash flow | 19.6% | -3.4% | -8.1% | -14.8% | 79.2% | |
| Capex / Depreciation | 71.9% | 17.3% | 45.5% | 87.6% | 198.3% | |
| Capex / Sales | 2.0% | 2.0% | 7.3% | 16.3% | 74.6% | |
| SG&A / Sales | 48.3% | 78.1% | 95.2% | 113.9% | 9.3% | |
| R&D / Sales | 5.6% | 27.6% | 38.2% | 39.2% | 0.0% | |
| Stock comp / Sales | 8.6% | 4.5% | 5.0% | 8.9% | 0.6% | |
| Intangibles / Total assets | 1.7% | 5.6% | 4.7% | 2.7% | 0.0% | |
| Days sales outstanding | 50d | 78d | 66d | 57d | 179d | |
| Days payables outstanding | 52d | 43d | 45d | 56d | 12d | |
| Operating cycle | 50d | 140d | 148d | 153d | 179d | |
| Cash conversion cycle | -2d | 97d | 104d | 97d | 167d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+6.8%EV / Sales ▼-51.2%EV / EBITDA ▲+1644.9%EV / Op. cash flow ▲+117.117Earnings yield ▼-0.031
Profitability
Return on equity ▼-1.045Return on assets ▲+0.342Return on invested capital ▲+1.097Return on capital employed ▲+1.487Operating ROA ▲+0.741Income quality ▼-2.091Tax burden ▲+6.901
Efficiency
Days sales outstanding ▼-27.722Days payables outstanding ▲+8.998Operating cycle ▼-89.586Cash conversion cycle ▼-98.584Capex / Sales -0.000R&D / Sales ▼-0.221
Balance-sheet strength
Current ratio ▲+6.544Net debt / EBITDA ▼-34.833Working capital ▲+820349000.000Invested capital ▲+780752000.000Intangibles / Total assets ▼-0.039
Change over 5 years
Valuation
Market cap ▲+1415.7%EV / Sales ▲+18.8%EV / EBITDA ▲+7233.8%EV / Op. cash flow ▲+78.644Earnings yield ▼-0.126
Profitability
Return on equity ▼-0.971Return on assets ▼-0.489Return on invested capital ▼-0.008Return on capital employed ▼-0.015Operating ROA ▲+0.011Income quality ▼-11.210Tax burden ▲+6.962
Efficiency
Days sales outstanding ▼-128.737Days payables outstanding ▲+40.264Operating cycle ▼-128.737Cash conversion cycle ▼-169.001Capex / Sales ▼-0.726R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+7.177Net debt / EBITDA ▼-43.452Working capital ▲+976243000.000Invested capital ▼-722564000.000Intangibles / Total assets n/a
Employee count
No employee-count data synced.
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-17 Caris Life Sciences: Diagnostics Growth With Room To Run Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships, leveraging them into new tests that I believe should increase their shareholder value in the long run. CAI''s Detect broadens its growth potential. However, we still need to see if their cash-pay adoption and marketing expenses pay off as intended.
- 2026-09-16 Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock? Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-09-08 Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner.
- 2026-09-02 Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea.
- 2026-08-27 Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
- 2026-08-27 Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature.
- 2026-08-06 Caris Life Sciences: Guidance Raised, Valuation Still Attractive Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris Detect reinforce the durability and breadth of CAI''s growth drivers. Valuation remains attractive and CAI trades at a discount to peers, with a fair value estimate of $30 per share by 2028.
- 2026-08-05 Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
- 2026-08-05 Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2 Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.54 per share a year ago.
- 2026-08-05 Caris Life Sciences Q2 Earnings Call Highlights Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization.